Overview

Effect of Tranexamic Acid in Upper Gastrointestinal Bleeding

Status:
Withdrawn
Trial end date:
2011-10-01
Target enrollment:
0
Participant gender:
All
Summary
The investigators hypothesize that addition of Tranexamic acid, an antifibrinolytic agent, to conventional therapy will lead to an improved outcome characterized by lower transfusion requirements.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Oklahoma
Treatments:
Tranexamic Acid
Criteria
Inclusion Criteria:

- All patients with GI bleed if the following criteria are met:

- has received 4 units of PRBCs within a 24-hour period, or

- has orthostatic hypotension (drop in SBP of 20mmHg or drop in DBP of 10mmHg after
fluid resuscitation with at least 20ml/Kg of either isotonic fluid and/or PRBCs),
or

- if the MAP remains below 60mmHg after fluid resuscitation, and

- written informed consent is obtained from the subject or legally authorized
representative.

Exclusion Criteria:

- Pregnant or lactating women

- Known to have gastrointestinal malignancy

- On anticoagulation therapy

- Patients with history of thromboembolism

- Patients with history of myocardial infarction or ischemic cerebrovascular accident

- Patient with end stage renal disease

- Patients with DNR status

- Incarcerated individuals